Episode 54
Biotech Hangout
00:00
Big Pharma in Major Biotech R&D Amount to 200 Billion Per Year
I'm with you this is such an odd setup in terms of having to make an FDA approval decision so close to confirmatory data. That's a pickle but it's the melphalan drug from Uncle Peptides I think something not too dissimilar happened. If big pharma want to know how powerful and clueless government buyers can be can do to your top line ask your colleagues who survived the brutal China's drug negotiation process 60% average discount on the extreme China's domestic PD ones are priced at 130th of the US PD ones. We had a few other questions and also I will as I'm reading just catching up on those if anybody wants to make any closing remarks because we
Transcript
Play full episode
